Patrick Poullet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Patrick Poullet has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Damarys Loew
Institut Curie, PSL Research University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France
4 shared publications - Emmanuel Barillot
Centre for Computational Biology (CBIO), Mines Paris, PSL University, Paris, France
3 shared publications Florent Dingli
Institut Curie, PSL Research University, Laboratoire de Spectrométrie de Masse Protéomique, Paris, France
3 shared publications- Anton James Enright
Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK
2 shared publications Celio Pouponnot
Institut Curie, PSL Research University, CNRS UMR, INSERM, Orsay, France; Université Paris Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021, Orsay, France
2 shared publicationsChristelle Dufour
Department of Pediatric and Adolescent Oncology, Gustave Roussy, Rue Edouard Vaillant, 94805 Villejuif, France
2 shared publications
Latest Publications
- Open Access
- 11 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A delayed translocation into the endoplasmic reticulum controls the post-translational modifications of PD-L1
N-terminal signal peptides (SPs) are traditionally considered as drivers of co-translational translocation of newly synthesised proteins into the endoplasmic reticulum (ER). However, growing evidences suggest that proteins with SPs can also undergo post-translational insertion into the ER membrane after synthesis is complete. Recently, an intermediate third mechanism has been uncovered where proteins with marginally hydrophobic or suboptimal SPs are translocated following an initial delay after translation initiation. Here, we show that this “delayed translocation” allows a temporary exposure of the nascent chain to the cytosolic environment, enabling exoplasmic domain modifications by cytosolic enzymes. We report that programmed death ligand-1 (PD-L1) follows this pathway, featuring a suboptimal SP that exposes its extracellular domain to the cytosol, enabling AMPK-dependent regulation of PD-L1 function. Importantly, optimising the SP of PD-L1 eliminates the cytosolic exposure, disrupting PD-L1’s trafficking and maturation, highlighting the physiological importance of the delayed translocation mechanism.
- 11 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA delayed translocation into the endoplasmic reticulum controls the post-translational modifications of PD-L1
N-terminal signal peptides (SPs) are traditionally considered as drivers of co-translational translocation of newly synthesised proteins into the endoplasmic reticulum (ER). However, growing evidences suggest that proteins with SPs can also undergo post-translational insertion into the ER membrane after synthesis is complete. Recently, an intermediate third mechanism has been uncovered where proteins with marginally hydrophobic or suboptimal SPs are translocated following an initial delay after translation initiation. Here, we show that this “delayed translocation” allows a temporary exposure of the nascent chain to the cytosolic environment, enabling exoplasmic domain modifications by cytosolic enzymes. We report that programmed death ligand-1 (PD-L1) follows this pathway, featuring a suboptimal SP that exposes its extracellular domain to the cytosol, enabling AMPK-dependent regulation of PD-L1 function. Importantly, optimising the SP of PD-L1 eliminates the cytosolic exposure, disrupting PD-L1’s trafficking and maturation, highlighting the physiological importance of the delayed translocation mechanism.
- Open Access
- 11 December 2023
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (24) , e113590
Extracellular vesicles and co‐isolated endogenous retroviruses from murine cancer cells differentially affect dendritic cells
Cells secrete extracellular vesicles (EVs) and non-vesicular extracellular (nano)particles (NVEPs or ENPs) that may play a role in intercellular communication. Tumor-derived EVs have been proposed to induce immune priming of antigen presenting cells or to be immuno-suppressive agents. We suspect that such disparate functions are due to variable compositions in EV subtypes and ENPs. We aimed to characterize the array of secreted EVs and ENPs of murine tumor cell lines. Unexpectedly, we identified virus-like particles (VLPs) from endogenous murine leukemia virus in preparations of EVs produced by many tumor cells. We established a protocol to separate small EVs from VLPs and ENPs. We compared their protein composition and analyzed their functional interaction with target dendritic cells. ENPs were poorly captured and did not affect dendritic cells. Small EVs specifically induced dendritic cell death. A mixed large/dense EV/VLP preparation was most efficient to induce dendritic cell maturation and antigen presentation. Our results call for systematic re-evaluation of the respective proportions and functions of non-viral EVs and VLPs produced by murine tumors and their contribution to tumor progression.
- 11 December 2023
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (24) , e113590
Open AccessExtracellular vesicles and co‐isolated endogenous retroviruses from murine cancer cells differentially affect dendritic cells
Cells secrete extracellular vesicles (EVs) and non-vesicular extracellular (nano)particles (NVEPs or ENPs) that may play a role in intercellular communication. Tumor-derived EVs have been proposed to induce immune priming of antigen presenting cells or to be immuno-suppressive agents. We suspect that such disparate functions are due to variable compositions in EV subtypes and ENPs. We aimed to characterize the array of secreted EVs and ENPs of murine tumor cell lines. Unexpectedly, we identified virus-like particles (VLPs) from endogenous murine leukemia virus in preparations of EVs produced by many tumor cells. We established a protocol to separate small EVs from VLPs and ENPs. We compared their protein composition and analyzed their functional interaction with target dendritic cells. ENPs were poorly captured and did not affect dendritic cells. Small EVs specifically induced dendritic cell death. A mixed large/dense EV/VLP preparation was most efficient to induce dendritic cell maturation and antigen presentation. Our results call for systematic re-evaluation of the respective proportions and functions of non-viral EVs and VLPs produced by murine tumors and their contribution to tumor progression.
- Open Access
- 3 November 2021
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 20, 100173
Quantitative Ubiquitylome Analysis Reveals the Specificity of RNF111/Arkadia E3 Ubiquitin Ligase for its Degradative Substrates SKI and SKIL/SnoN in TGF-β Signaling Pathway
- 3 November 2021
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 20, 100173
Open AccessQuantitative Ubiquitylome Analysis Reveals the Specificity of RNF111/Arkadia E3 Ubiquitin Ligase for its Degradative Substrates SKI and SKIL/SnoN in TGF-β Signaling Pathway
- 18 November 2019
- Published by Springer Nature in Molecular Psychiatry
- Vol. 25 (1) , 22-36
Life-long epigenetic programming of cortical architecture by maternal ‘Western’ diet during pregnancy
The evolution of human diets led to preferences toward polyunsaturated fatty acid (PUFA) content with ‘Western’ diets enriched in ω-6 PUFAs. Mounting evidence points to ω-6 PUFA excess limiting metabolic and cognitive processes that define longevity in humans. When chosen during pregnancy, ω-6 PUFA-enriched ‘Western’ diets can reprogram maternal bodily metabolism with maternal nutrient supply precipitating the body-wide imprinting of molecular and cellular adaptations at the level of long-range intercellular signaling networks in the unborn fetus. Even though unfavorable neurological outcomes are amongst the most common complications of intrauterine ω-6 PUFA excess, cellular underpinnings of life-long modifications to brain architecture remain unknown. Here, we show that nutritional ω-6 PUFA-derived endocannabinoids desensitize CB1 cannabinoid receptors, thus inducing epigenetic repression of transcriptional regulatory networks controlling neuronal differentiation. We found that cortical neurons lose their positional identity and axonal selectivity when mouse fetuses are exposed to excess ω-6 PUFAs in utero. Conversion of ω-6 PUFAs into endocannabinoids disrupted the temporal precision of signaling at neuronal CB1 cannabinoid receptors, chiefly deregulating Stat3-dependent transcriptional cascades otherwise required to execute neuronal differentiation programs. Global proteomics identified the immunoglobulin family of cell adhesion molecules (IgCAMs) as direct substrates, with DNA methylation and chromatin accessibility profiling uncovering epigenetic reprogramming at >1400 sites in neurons after prolonged cannabinoid exposure. We found anxiety and depression-like behavioral traits to manifest in adult offspring, which is consistent with genetic models of reduced IgCAM expression, to suggest causality for cortical wiring defects. Overall, our data uncover a regulatory mechanism whose disruption by maternal food choices could limit an offspring’s brain function for life.
- 18 November 2019
- Published by Springer Nature in Molecular Psychiatry
- Vol. 25 (1) , 22-36
Life-long epigenetic programming of cortical architecture by maternal ‘Western’ diet during pregnancy
The evolution of human diets led to preferences toward polyunsaturated fatty acid (PUFA) content with ‘Western’ diets enriched in ω-6 PUFAs. Mounting evidence points to ω-6 PUFA excess limiting metabolic and cognitive processes that define longevity in humans. When chosen during pregnancy, ω-6 PUFA-enriched ‘Western’ diets can reprogram maternal bodily metabolism with maternal nutrient supply precipitating the body-wide imprinting of molecular and cellular adaptations at the level of long-range intercellular signaling networks in the unborn fetus. Even though unfavorable neurological outcomes are amongst the most common complications of intrauterine ω-6 PUFA excess, cellular underpinnings of life-long modifications to brain architecture remain unknown. Here, we show that nutritional ω-6 PUFA-derived endocannabinoids desensitize CB1 cannabinoid receptors, thus inducing epigenetic repression of transcriptional regulatory networks controlling neuronal differentiation. We found that cortical neurons lose their positional identity and axonal selectivity when mouse fetuses are exposed to excess ω-6 PUFAs in utero. Conversion of ω-6 PUFAs into endocannabinoids disrupted the temporal precision of signaling at neuronal CB1 cannabinoid receptors, chiefly deregulating Stat3-dependent transcriptional cascades otherwise required to execute neuronal differentiation programs. Global proteomics identified the immunoglobulin family of cell adhesion molecules (IgCAMs) as direct substrates, with DNA methylation and chromatin accessibility profiling uncovering epigenetic reprogramming at >1400 sites in neurons after prolonged cannabinoid exposure. We found anxiety and depression-like behavioral traits to manifest in adult offspring, which is consistent with genetic models of reduced IgCAM expression, to suggest causality for cortical wiring defects. Overall, our data uncover a regulatory mechanism whose disruption by maternal food choices could limit an offspring’s brain function for life.
- 1 September 2018
- Published by Elsevier in Cancer Cell
- Vol. 34 (3) , 379-395.e7
Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling
- 1 September 2018
- Published by Elsevier in Cancer Cell
- Vol. 34 (3) , 379-395.e7
Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling
- 6 November 2017
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (suppl_6) , vi52-vi53
CSIG-15. PROTEOMIC AND PHOSPHOPROTEOMIC ANALYSIS OF HUMAN MEDULLOBLASTOMA REVEALS DISTINCT ACTIVATED PATHWAYS BETWEEN SUBGROUPS
Deregulations in fundamental signaling pathways are key events in pathogenesis of cancer. One intriguing illustration that still holds blind spots is the pediatric brain tumor arising from the developing cerebellum: medulloblastoma (MB). Extensive high-throughput sequencing led to the characterization of four MB subgroups (WNT, SHH, Group 3 and Group 4) delineated with distinct molecular signatures and clinical outcomes. However, up-to-date these analyses have not attained the global comprehension of their dynamic network complexity. Wishing to get a comprehensive view of all MB subgroups we employed a multi-scale analysis to integrate genomic copy number (CN), DNA methylation, mRNA, protein and phosphorylation levels across 38 flash frozen primary human MBs (5 WNT, 10 SHH, 10 Group 3 and 13 Group 4). Our proteomic analysis allows to distinguish the four MB subgroups. Interestingly, Group 4 MB is particularly distinguishable from the other subgroups based on phosphorylation profile. Moreover, integration of all omic layers by similarity network fusion allowed precise definition of the four subgroups. Correlation studies between CN, RNA and protein levels showed convergent effects of CN alterations toward cell cycle, RNA and nucleotide metabolism. Importantly, protein levels were poorly predicted by levels of corresponding mRNA with consequence on active pathway prediction. This observation was of particular importance in Group 4 MB in which protein and phosphorylation levels allowed the identification of pathways that were unable to be predicted by RNA data. Ultimately, this led us to the characterization of potential biomarkers of Group 4 MB and promising targetable pathways across subgroups. Altogether, combined multi-scale analyses of MB have allowed us to identify and prioritize novel molecular drivers involved in human MB genesis and progression.
- 6 November 2017
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (suppl_6) , vi52-vi53
CSIG-15. PROTEOMIC AND PHOSPHOPROTEOMIC ANALYSIS OF HUMAN MEDULLOBLASTOMA REVEALS DISTINCT ACTIVATED PATHWAYS BETWEEN SUBGROUPS
Deregulations in fundamental signaling pathways are key events in pathogenesis of cancer. One intriguing illustration that still holds blind spots is the pediatric brain tumor arising from the developing cerebellum: medulloblastoma (MB). Extensive high-throughput sequencing led to the characterization of four MB subgroups (WNT, SHH, Group 3 and Group 4) delineated with distinct molecular signatures and clinical outcomes. However, up-to-date these analyses have not attained the global comprehension of their dynamic network complexity. Wishing to get a comprehensive view of all MB subgroups we employed a multi-scale analysis to integrate genomic copy number (CN), DNA methylation, mRNA, protein and phosphorylation levels across 38 flash frozen primary human MBs (5 WNT, 10 SHH, 10 Group 3 and 13 Group 4). Our proteomic analysis allows to distinguish the four MB subgroups. Interestingly, Group 4 MB is particularly distinguishable from the other subgroups based on phosphorylation profile. Moreover, integration of all omic layers by similarity network fusion allowed precise definition of the four subgroups. Correlation studies between CN, RNA and protein levels showed convergent effects of CN alterations toward cell cycle, RNA and nucleotide metabolism. Importantly, protein levels were poorly predicted by levels of corresponding mRNA with consequence on active pathway prediction. This observation was of particular importance in Group 4 MB in which protein and phosphorylation levels allowed the identification of pathways that were unable to be predicted by RNA data. Ultimately, this led us to the characterization of potential biomarkers of Group 4 MB and promising targetable pathways across subgroups. Altogether, combined multi-scale analyses of MB have allowed us to identify and prioritize novel molecular drivers involved in human MB genesis and progression.
- Open Access
- 30 May 2014
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 5, 152
Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial
Precision medicine (PM) requires the delivery of individually adapted medical care based on the genetic characteristics of each patient and his/her tumor. The last decade witnessed the development of high-throughput technologies such as microarrays and next-generation sequencing which paved the way to PM in the field of oncology. While the cost of these technologies decreases, we are facing an exponential increase in the amount of data produced. Our ability to use this information in daily practice relies strongly on the availability of an efficient bioinformatics system that assists in the translation of knowledge from the bench towards molecular targeting and diagnosis. Clinical trials and routine diagnoses constitute different approaches, both requiring a strong bioinformatics environment capable of i) warranting the integration and the traceability of data, ii) ensuring the correct processing and analyses of genomic data and iii) applying well-defined and reproducible procedures for workflow management and decision-making. To address the issues, a seamless information system was developed at Institut Curie which facilitates the data integration and tracks in real-time the processing of individual samples. Moreover, computational pipelines were developed to identify reliably genomic alterations and mutations from the molecular profiles of each patient. After a rigorous quality control, a meaningful report is delivered to the clinicians and biologists for the therapeutic decision. The complete bioinformatics environment and the key points of its implementation are presented in the context of the SHIVA clinical trial, a multicentric randomized phase II trial comparing targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer. The numerous challenges faced in practice during the setting up and the conduct of this trial are discussed as an illustration of PM application.
- 30 May 2014
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 5, 152
Open AccessBioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial
Precision medicine (PM) requires the delivery of individually adapted medical care based on the genetic characteristics of each patient and his/her tumor. The last decade witnessed the development of high-throughput technologies such as microarrays and next-generation sequencing which paved the way to PM in the field of oncology. While the cost of these technologies decreases, we are facing an exponential increase in the amount of data produced. Our ability to use this information in daily practice relies strongly on the availability of an efficient bioinformatics system that assists in the translation of knowledge from the bench towards molecular targeting and diagnosis. Clinical trials and routine diagnoses constitute different approaches, both requiring a strong bioinformatics environment capable of i) warranting the integration and the traceability of data, ii) ensuring the correct processing and analyses of genomic data and iii) applying well-defined and reproducible procedures for workflow management and decision-making. To address the issues, a seamless information system was developed at Institut Curie which facilitates the data integration and tracks in real-time the processing of individual samples. Moreover, computational pipelines were developed to identify reliably genomic alterations and mutations from the molecular profiles of each patient. After a rigorous quality control, a meaningful report is delivered to the clinicians and biologists for the therapeutic decision. The complete bioinformatics environment and the key points of its implementation are presented in the context of the SHIVA clinical trial, a multicentric randomized phase II trial comparing targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer. The numerous challenges faced in practice during the setting up and the conduct of this trial are discussed as an illustration of PM application.
- 1 June 2011
- Published by Elsevier in Molecular Cell
- Vol. 42 (5) , 650-661
SH3BP1, an Exocyst-Associated RhoGAP, Inactivates Rac1 at the Front to Drive Cell Motility
- 1 June 2011
- Published by Elsevier in Molecular Cell
- Vol. 42 (5) , 650-661
SH3BP1, an Exocyst-Associated RhoGAP, Inactivates Rac1 at the Front to Drive Cell Motility
- 23 July 2007
- Published by Wiley in Proteomics
- Vol. 7 (15) , 2553-2556
my ProMS, a web server for management and validation of mass spectrometry‐based proteomic data
Curation and interpretation of protein databank‐search results by human experts are key aspects of MS‐based proteomic data acquisition. These tasks are often overlooked due to the vast amount of data to inspect. We have developed my ProMS, a web server designed to ease search results validation and interpretation by improving data organization, mining and sharing between MS specialists and biologists during MS‐based collaborative projects. A demo is accessible at http://bioinfo.curie.fr/myproms.
- 23 July 2007
- Published by Wiley in Proteomics
- Vol. 7 (15) , 2553-2556
my ProMS, a web server for management and validation of mass spectrometry‐based proteomic data
Curation and interpretation of protein databank‐search results by human experts are key aspects of MS‐based proteomic data acquisition. These tasks are often overlooked due to the vast amount of data to inspect. We have developed my ProMS, a web server designed to ease search results validation and interpretation by improving data organization, mining and sharing between MS specialists and biologists during MS‐based collaborative projects. A demo is accessible at http://bioinfo.curie.fr/myproms.
- Open Access
- 25 November 2004
- Published by Wiley in Molecular Microbiology
- Vol. 55 (1) , 184-186
PfPK7, an atypical MEK‐related protein kinase, reflects the absence of classical three‐component MAPK pathways in the human malaria parasite Plasmodium falciparum
Summary: Two members of the mitogen‐activated protein kinase (MAPK) family have been previously characterized in Plasmodium falciparum, but in vitro attempts at identifying MAP kinase kinase (MAPKK) homologues have failed. Here we report the characterization of a novel plasmodial protein kinase, PfPK7, whose top scores in blastp analysis belong to the MAPKK3/6 subgroup of MAPKKs. However, homology to MAPKKs is restricted to regions of the C‐terminal lobe of the kinase domain, whereas the N‐terminal region is closer to fungal protein kinase A enzymes (PKA, members of the AGC group of protein kinases). Hence, PfPK7 is a ‘composite’ enzyme displaying regions of similarity to more than one protein kinase family, similar to a few other plasmodial protein kinases. PfPK7 is expressed in several developmental stages of the parasite, both in the mosquito vector and in the human host. Recombinant PfPK7 displayed kinase activity towards a variety of substrates, but was unable to phosphorylate the two P. falciparum MAPK homologues in vitro, and was insensitive to PKA and MEK inhibitors. Together with the absence of a typical MAPKK activation site in its T‐loop, this suggests that PfPK7 is not a MAPKK orthologue, despite the fact that this enzyme is the most ‘MAPKK‐like’ enzyme encoded in the P. falciparum genome. This is consistent with recent observations that the plasmodial MAPKs are not true orthologues of the ERK1/2, p38 or JNK MAPKs, and strengthens the evidence that classical three‐component module‐dependent MAPK signalling pathways do not operate in malaria parasites, a feature that has not been described in any other eukaryote.
- 25 November 2004
- Published by Wiley in Molecular Microbiology
- Vol. 55 (1) , 184-186
Open AccessPfPK7, an atypical MEK‐related protein kinase, reflects the absence of classical three‐component MAPK pathways in the human malaria parasite Plasmodium falciparum
Summary: Two members of the mitogen‐activated protein kinase (MAPK) family have been previously characterized in Plasmodium falciparum, but in vitro attempts at identifying MAP kinase kinase (MAPKK) homologues have failed. Here we report the characterization of a novel plasmodial protein kinase, PfPK7, whose top scores in blastp analysis belong to the MAPKK3/6 subgroup of MAPKKs. However, homology to MAPKKs is restricted to regions of the C‐terminal lobe of the kinase domain, whereas the N‐terminal region is closer to fungal protein kinase A enzymes (PKA, members of the AGC group of protein kinases). Hence, PfPK7 is a ‘composite’ enzyme displaying regions of similarity to more than one protein kinase family, similar to a few other plasmodial protein kinases. PfPK7 is expressed in several developmental stages of the parasite, both in the mosquito vector and in the human host. Recombinant PfPK7 displayed kinase activity towards a variety of substrates, but was unable to phosphorylate the two P. falciparum MAPK homologues in vitro, and was insensitive to PKA and MEK inhibitors. Together with the absence of a typical MAPKK activation site in its T‐loop, this suggests that PfPK7 is not a MAPKK orthologue, despite the fact that this enzyme is the most ‘MAPKK‐like’ enzyme encoded in the P. falciparum genome. This is consistent with recent observations that the plasmodial MAPKs are not true orthologues of the ERK1/2, p38 or JNK MAPKs, and strengthens the evidence that classical three‐component module‐dependent MAPK signalling pathways do not operate in malaria parasites, a feature that has not been described in any other eukaryote.